REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.
INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal; ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
J Control Release. 2014 Sep 10;189:169-86. doi: 10.1016/j.jconrel.2014.06.020. Epub 2014 Jun 23.
Helicobacter pylori is the major cause of chronic gastritis and peptic ulcers. Since the classification as a group 1 carcinogenic by International Agency for Research on Cancer, the importance of the complete H. pylori eradication has obtained a novel meaning. Hence, several studies have been made in order to deepen the knowledge in therapy strategies. However, the current therapy presents unsatisfactory eradication rates due to the lack of therapeutic compliance, antibiotic resistance, the degradation of antibiotics at gastric pH and their insufficient residence time in the stomach. Novel approaches have been made in order to overcome these limitations. The purpose of this review is to provide an overview about the current therapy and its limitations, while highlighting the possibility of using micro- and nanotechnology to develop gastric drug delivery systems, overcoming these difficulties in the future.
幽门螺杆菌是慢性胃炎和消化性溃疡的主要病因。自从被国际癌症研究机构列为 1 类致癌物质以来，彻底根除幽门螺杆菌的重要性获得了新的意义。因此，为了加深对治疗策略的认识，已经进行了多项研究。然而，由于治疗依从性差、抗生素耐药性、抗生素在胃内 pH 值下降以及在胃内停留时间不足，目前的治疗方法未能达到令人满意的根除率。为了克服这些限制，已经提出了一些新的方法。本文旨在概述目前的治疗方法及其局限性，同时强调利用微纳米技术开发胃内药物传递系统的可能性，以期在未来克服这些困难。
